Introduction Peptide-oligonucleotide conjugates gain entry into cells mainly through energy-dependent endocytosis or energy-independent direct plasma membrane translocation, with the dominant […]
Introduction Obtaining approval for an Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) requires manufacturers
Introduction: Peptide Characterization Services play a critical role in the successful development of biosimilars and complex peptide therapeutics. Regulatory agencies
Peptide Characterization Services for Biosimilar and Complex Drug Applications Read More »
Introduction Method Validation for Leachables Testing in a Good Manufacturing Practice (GMP) laboratory provides documented, objective evidence that an analytical
Method Validation for Leachables Testing: What Regulators Expect from a GMP Lab Read More »
Introduction: Anyone comparing an antisense oligonucleotide vs peptide-oligonucleotide conjugate is really asking a structural question: is the therapeutic molecule a
Introduction Producing audit-ready Extractables and Leachables (E&L) data depends on a scientifically defensible, cGMP-compliant testing architecture capable of proving that
Introduction How to Choose a Peptide CDMO? Sponsoring organizations must perform a comprehensive technical audit that assesses chemical synthesis platforms,
Introduction: For sponsors planning an Abbreviated New Drug Application (ANDA) or Abbreviated New Drug Submission (ANDS), one of the first
How Long Does Generic Drug Development Take at a CDMO? Timeline Expectations Explained Read More »
